Oncology and Infusion Services revenue cycle services for authorized therapy, accurate drug billing, and stronger cash control.
Revenue cycle performance for outpatient oncology centers, hospital infusion suites, specialty drug programs, radiation oncology, medical oncology practices, and health system cancer programs depends on benefits verification, prior authorization, regimen validation, drug coverage, patient affordability, documentation specificity, oncology coding, infusion charge capture, J-code accuracy, wastage documentation, clean claims, denial prevention, underpayment detection, and focused A/R follow-up. Our operating model helps revenue cycle leaders protect high-cost therapy reimbursement before defects become avoidable leakage.
7 of top 20
U.S. health systems served
32M+
Coding charts processed annually
28M+
A/R claims managed annually
Therapy revenue cycles need authorization, drug, and charge discipline before care becomes margin risk.
Oncology and infusion services workflows carry high financial sensitivity because treatment plans, drug acquisition costs, payer rules, prior authorization, medical necessity, coding, charge capture, patient assistance, and payment variance all intersect before the claim pays. Leakage can enter through missing regimen authorization, unclear diagnosis specificity, NDC or J-code mismatch, infusion time errors, drug wastage gaps, late charges, payer policy changes, underpayments, and aged balances. We support provider organizations with practitioner-led operations, workflow intelligence, and governance that connects access, coding, charge integrity, denials, and cash outcomes.
Secure treatment financially before therapy starts
Protect drug and infusion reimbursement with charge discipline
Resolve denials and underpayments tied to payer and regimen rules
Specialty-specific support across every oncology and infusion handoff.
Oncology and infusion services programs need revenue cycle services that understand referral intake, benefits verification, prior authorization, regimen changes, oral and infused drug coverage, patient estimates, financial counseling, medical necessity, diagnosis specificity, chemotherapy and biologic coding, infusion administration coding, J-codes, NDCs, units, modifiers, drug wastage, charge reconciliation, payer edits, denials, underpayments, secondary billing, and patient balance follow-up. We organize support by where risk enters the therapy encounter so front-office, mid-office, and back-office revenue cycle support for oncology and infusion services providers stays connected from treatment planning through payment.
Front-office
Therapy access, coverage, and authorization validation - fewer payer and affordability defects before treatment.
Mid-office
Coding, documentation, and drug charge controls - cleaner oncology claims and lower leakage exposure.
Back-office
Claim, payment, denial, and variance resolution - faster cash with fewer repeated therapy-specific defects.
Authorized therapy. Accurate drug charges. Fewer preventable denials.
Clear treatment financially before therapy begins
Referral intake, eligibility and benefits verification, prior authorization, price transparency and patient estimates, and financial clearance and counseling - so coverage, regimen authorization, patient responsibility, and assistance pathways support treatment before the encounter.
Convert therapy, drugs, and administration into accurate reimbursement
Medical coding, coding audits and quality assurance, charge capture optimization, revenue integrity and leakage prevention, and billing compliance and audit defense - so CPT, HCPCS, J-codes, NDCs, units, modifiers, infusion time, and drug wastage align before claim submission.
Prevent oncology denials before appeal volume grows
Claims editing and clean-claim validation, claim submission and clearinghouse support, and denials management and appeals - so authorization, medical necessity, coding, drug, unit, modifier, and payer-edit issues get corrected earlier.
Recover high-cost therapy dollars with payer variance visibility
Payment posting and reconciliation plus underpayment recovery and payer variance resolution - so contractual shortfalls, drug carve-outs, secondary billing, COB issues, and aged therapy balances move with clear root-cause ownership.
One operating model. Three pillars. Every engagement.
Expertise-led
Specialists who understand oncology access, infusion coding, drug billing, payer edits, and variance recovery - not task queues in isolation.
- Referral, authorization, coding, charge review, billing, denial, payment, and A/R practitioners who work from therapy-specific playbooks
- A named engagement lead who connects treatment readiness, claim quality, denial prevention, underpayment recovery, and cash outcomes
- SME calibration across drug coverage, CPT and HCPCS coding, J-codes, NDCs, infusion documentation, medical necessity, payer edits, and compliance expectations
Technology-powered
RevAmp intelligence that turns treatment and claim signals into earlier action - so leakage shows up before it repeats across regimens.
- Rules-driven prioritization across authorization gaps, regimen changes, coding holds, claim edits, drug charge issues, denials, underpayments, and A/R inventory
- Dashboards that connect productivity, quality, therapy trends, payer behavior, denial reasons, payment variance, and cash movement
- Automation that reduces repeat manual touches while preserving practitioner judgment for complex therapies, drugs, units, and payer rules
Operationally-governed
Accountability with cadence, evidence, and ownership - not static reporting after balances age.
- KPI reviews tied to treatment readiness, authorization outcomes, coding accuracy, charge lag, clean-claim rate, denial rate, underpayment recovery, and A/R aging
- Quality audits and corrective action loops that reduce repeat defects by regimen, location, payer, drug, and workflow source
- Transparent operating reviews with visibility into queues, exceptions, escalations, ownership, and financial results
Our Vision
Open Accountability: Taking responsibility without taking control.
Oncology revenue cycle leaders should not have to choose between operational control and partner accountability. You keep control of systems, treatment workflows, payer strategy, clinical protocols, pharmacy coordination, compliance requirements, and performance priorities. We bring trained capacity, technology support, quality controls, and governance to improve metrics we agree to own across modular support, co-managed operations, or end-to-end partnership.
Treatment readiness rate
Clean eligibility, authorization, estimate, and counseling data before therapy
Coding accuracy
CPT, HCPCS, J-code, NDC, diagnosis, unit, and modifier quality strengthened
Drug charge capture quality
Medication, administration, wastage, and unit charges reconciled faster
Denial rate and overturn yield
Therapy-related payer defects reduced with stronger evidence
Underpayment recovery
Drug carve-outs, contractual shortfalls, and payer variance resolved faster
Why Us
What sets our oncology revenue cycle approach apart.
When oncology revenue cycle work runs as isolated queues, regimen authorization gaps, coverage changes, drug coding errors, unit defects, missed wastage, charge lag, claim edits, underpayments, and aged balances spread across therapies before leaders see the pattern. Our first-pass performance model connects the work earlier so each defect gets corrected where it starts, not only where it appears financially.
Rework-Powered Cleanup Machine
Our First-Pass Performance
Front-end accuracy
Referral, authorization, coverage, estimate, and counseling defects surface after therapy or after billing.
Referral intake, eligibility, authorization, estimates, and financial clearance are tightened before treatment.
Documentation and coding
Diagnosis gaps, infusion time issues, J-code errors, unit defects, and wastage gaps trigger edits and rebills.
Coding, charge review, revenue integrity, and compliance checks align to therapy and payer requirements.
Denial management
Appeal teams absorb repeating denials from authorization, medical necessity, drug, coding, unit, and payer-edit defects.
Denial reasons feed back into access, regimen validation, coding, charging, claim edits, and payer rules.
Cash acceleration
A/R follow-up works old therapy balances without always identifying why accounts stalled.
Prioritized queues move payer and patient balances while variance, secondary billing, and defect sources are closed.
Audit readiness
Evidence gets assembled after a payer questions therapy necessity, drug billing, units, or payment.
Authorization, order, documentation, J-code, NDC, charge, claim, and appeal evidence stays organized from the start.
Revenue cycle thinking for leaders who need fewer surprises.
Explore Vee Healthtek perspectives on the forces reshaping revenue cycle performance, healthcare operations, technology adoption, and financial resilience.
Find where oncology revenue leakage enters the therapy encounter.
Schedule a 30-minute working session with an oncology revenue cycle lead. Bring one pressure point - regimen authorization, drug coverage, patient affordability, infusion coding, J-code variation, NDC capture, wastage documentation, payer edits, underpayments, or aged A/R. We will map where the defect begins, how it affects reimbursement, and how a connected operating model can stabilize performance across therapies without taking control away from your team.
Continue exploring expert perspectives, industry trends, and practical strategies for improving revenue cycle performance.
Explore Points Of ViewFrequently Asked Questions
What makes oncology and infusion services revenue cycle management different from other specialties?
Can you support only one part of our therapy revenue cycle?
Which Electronic Health Records (EHRs) and Electronic Medical Records (EMRs) do you support?
How do you reduce oncology denials without simply adding more appeals staff?
Do you provide offshore revenue cycle management for oncology and infusion services providers?
What KPIs should leaders track for oncology revenue cycle management services?
How does RevAmp fit into existing oncology revenue cycle systems?